

Clinical Trials in HK – Lung Cancer

No	Institution	Trial name	Cancer Site	Experimental Treatment Agent	Key Eligibility Criteria	Study Coordinator Contact	Status
1	PYNEH	A Single-arm Phase II Study to Determine the Efficacy of Preemptive Local Ablative Therapy to Residual Metabolic Active Oligo-metastases in Those EGFR Mutation Positive Non-small Cell Lung Cancer Patients Who Have Achieved a Good Partial Response With First-line EGFR TKI [ATOM]	Lung	Radiation: preemptive local ablative therapy	<ol style="list-style-type: none"> 1. NSCLC 2. Activating EGFR Mutation 3. Achieved PR with TKI 	Christine Tse Mandy Wong 2595 4183	Open
2	PYNEH	A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-III A Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy [ADAURA]	Lung	AZD9291	Stage IB-III A Non-small Cell Lung Carcinoma	Christine Tse Mandy Wong 2595 4183	Open
3	QEH	A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer	Lung	Nivolumab, Ipilimumab, Placebo	<ol style="list-style-type: none"> 1. Extensive stage of small cell lung carcinoma 2. Received 4 cycles of platinum-based, 	Leann 3506 2851	Open

		(ED-SCLC) after Completion of Platinum-based First Line Chemotherapy CA209- 451			first-line chemo with response CR, PR, SD 3. Minimum 10 slides of Tumor biopsy		
4	QEH	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor <i>NTRK1/2/3</i> , <i>ROS1</i> , or <i>ALK</i> Gene Rearrangements RXDX-101-02	Lung	Single arm entrectinib	1. Solid tumors (any line of therapy) 2. Positive for NTRK1/ 2/ 3, ROS1 and ALK 3. ROS1 naïve 4. ALK or ROS1 (previously treated w/ crizotinib), CNS-only progression	Leann Au 3506 2851	Recruitment ongoing
5	QEH	XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer(NSCLC) Patients	Lung	X-396 or Crizotinib	1. Stage IIIB or IV NSCLC 2. ALK +ve by FISH or IHC 3. No prior TKI treatment (For prior tx, only accept 1 regimen of systemic anticancer therapy) 4. ECOG ≤2	Kipo Wan 3506 2413	Open
6	QEH	A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-III A Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without	Lung	AZD9291/Placebo	1. classified post-operatively as Stage IB, II or IIIA on the basis of the pathologic criteria 2. Confirmation that the tumor harbours one of the 2 common EGFR	Kipo Wan 3506 2413	Open

		Adjuvant Chemotherapy(ADAURA)			mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M		
7	QEH	A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer [Protocol No.: I4T-MC-JVCY]	Lung	Ramucirumab	<ol style="list-style-type: none"> 1. Untreated NSCLC with EGFR Positive (Exon 19 deletion or exon 21 'L858R') 2. Stage IV disease 	Apple Cheung 3506 2414	Open